Herndon, Virginia – November 05, 2025 – PRESSADVANTAGE –
Elegant Kitchen and Bath, a licensed contractor specializing in home renovation services, announces the expansion of its service coverage to meet increasing demand for kitchen and bathroom remodeling projects throughout Virginia. The expansion includes enhanced service availability in Ashburn and seventeen additional communities across the region.
The company provides seven categories of remodeling services: basement remodeling, bathroom remodeling, countertop installation, decking, home addition remodeling, kitchen remodeling, and pergolas and winter gardens. Each project follows a standardized process beginning with consultation and design planning, followed by construction and installation phases.
For Kitchen Renovation Ashburn projects, the company employs a comprehensive project management approach that coordinates all construction phases from initial demolition through final installation. This includes coordination of plumbing, electrical work, and fixture placement. The single-contractor model reduces project timelines by an average of 20 percent compared to multi-contractor arrangements, according to industry data from the National Association of Home Builders.
“The expansion allows us to serve more homeowners who require professional remodeling services,” said Arif Zararsız, Vice President of Elegant Kitchen and Bath. “We have structured our operations to provide consistent service delivery across all communities, ensuring each project receives appropriate resources and attention regardless of location.”
The expansion comes as housing market data shows continued investment in home improvements across Virginia. The Remodeling Market Index indicates that professional remodeling activity in the region has increased 12 percent year-over-year, with kitchen and bathroom projects accounting for the majority of renovation spending.
For Best Kitchen Remodeling Ashburn services, the company utilizes materials from established suppliers, including granite, marble, and quartz for countertops, along with cabinetry and flooring options. All installations follow Virginia building codes and industry standards established by the National Kitchen and Bath Association.
“Each home presents specific structural and design considerations that require customized planning,” added Zararsız. “Our expansion enables us to apply our project management methodology to more communities while maintaining consistent quality standards across all service areas.”
The company’s expanded service area now encompasses Herndon, Chantilly, Centreville, Reston, Sterling, Great Falls, Ashburn, Fairfax, McLean, Manassas, Haymarket, Burke, Vienna, Falls Church, Annandale, Springfield, Alexandria, and Arlington. This geographic expansion responds to growing regional demand for professional remodeling services, as recent industry reports indicate kitchen and bathroom renovations represent 35 percent of all home improvement projects in Virginia.
As the Best Remodeling Company Virginia residents can access for comprehensive renovation projects, Elegant Kitchen and Bath maintains the required licensing and insurance coverage in accordance with state regulations. The company provides detailed project proposals with transparent pricing structures for all renovation work.
Elegant Kitchen and Bath is a Virginia-based remodeling contractor providing renovation services for kitchens, bathrooms, basements, and home additions. The company combines design planning with construction services to deliver complete remodeling projects. Their team manages projects from initial consultation through final completion for residential clients throughout Virginia.
###
For more information about Elegant Kitchen and Bath, contact the company here:
Elegant Kitchen and Bath Elegant Kitchen and Bath LLC (703)-763-4277 info@elegantkitchenbath.com 2465 Centreville Rd. J21, Herndon, VA 20171
NORTH FOND DU LAC, WI – October 27, 2025 – PRESSADVANTAGE –
FZE Manufacturing, a leader in providing innovative manufacturing solutions, today announces the availability of its official YouTube channel. This platform aims to enhance accessibility to the company’s expertise and industry insights through visual content tailored to diverse audiences interested in manufacturing processes, advancements, and best practices. The channel will serve as a centralized hub for educational content that addresses both fundamental concepts and emerging industry trends.
FZE’s YouTube channel features a range of content, including tutorials, behind-the-scenes looks at manufacturing techniques, and expert interviews. By utilizing this medium, FZE Manufacturing seeks to engage with both seasoned professionals and newcomers to the field, fostering a comprehensive understanding of the industry’s evolving landscape. The content will be regularly updated to reflect current industry standards and technological developments, ensuring viewers receive the most relevant and timely information available.
“This channel allows us to share valuable knowledge and connect with our audience more dynamically,” said Doug Pribyl, CEO of FZE Manufacturing. “We believe that visual storytelling can effectively demonstrate the complexities and innovations of our work.”
The initiative reflects a growing trend among manufacturing companies harnessing digital platforms to reach broader audiences. As technology continues to reshape communication, FZE Manufacturing recognizes the need to adapt and leverage these channels for educational purposes. The company’s commitment to digital innovation extends beyond the YouTube channel to encompass a comprehensive strategy for multi-platform engagement.
In addition to tutorials and discussions on manufacturing techniques, the channel includes profiles of various projects undertaken by the company, showcasing the practical applications of their solutions. By highlighting real-world scenarios, FZE Manufacturing aims to provide context and demonstrate the tangible impact of their innovations. These real-life studies will span multiple applications, illustrating the versatility and effectiveness of modern manufacturing approaches across different sectors
“We want to bridge the gap between theory and practice,” Doug Pribyl CEO stated. “By showing how our technologies are applied in real-time, we hope to inspire and educate the next generation of manufacturers.” The company anticipates that this approach will attract a wider audience, including students and educators, interested in exploring manufacturing careers.
Elemental to the vision for the channel is the commitment to ongoing learning and development within the industry. The content is designed to not only inform but also spark discussions among viewers, encouraging feedback and interaction. This approach aligns with FZE Manufacturing’s efforts to cultivate a knowledgeable community around manufacturing.
As the channel grows, FZE Manufacturing plans to incorporate viewer suggestions into future content, enhancing the relevance and value of each video. The ability to adapt to audience preferences underscores the company’s focus on interactive engagement and education, ensuring content remains aligned with industry advancements. Interactive features such as comments and community posts will facilitate meaningful dialogue between the company and its audience.
FZE Manufacturing invites viewers to subscribe to the channel for updates on new videos and content focused on various aspects of the manufacturing process. This innovative communication strategy seeks to foster a deeper appreciation for the complexities and achievements within the manufacturing sector. Subscribers will gain access to announcements of exclusive content and special announcements about company initiatives.
The YouTube channel serves as a testament to FZE Manufacturing’s dedication to bridging the gaps in manufacturing education and workforce development. By leveraging modern technology, the company positions itself not only as a manufacturing leader but also as a source of valuable resources and insights for the industry at large.
###
For more information about FZE Manufacturing Solutions LLC, contact the company here:
FZE Manufacturing Solutions Doug Pribyl 920-921-4084 info@fzemanufacturing.com 528 Harrison Court North Fond du Lac, WI 54937
The Light System (TLS) has issued a formal statement regarding the lawsuit filed by Energy Enhancement Systems (EES) against center owner Susan Bowman, as first reported by LA Weekly. TLS affirms its support for Bowman and other practitioners who have invested in light and frequency-based wellness systems in good faith and who now face legal and financial pressure as a result of EES’s actions.
According to LA Weekly, EES filed a lawsuit accusing Bowman of making unauthorized modifications to her system. Bowman has stated that many other center owners made similar adjustments without facing legal action. She believes that the real reason she was targeted is because she spoke publicly about the technology’s origins, pointing to evidence showing that Sandra Rose Michael is not the inventor, and identifying Robert J. Religa as the original creator.
Religa, the documented inventor of the technology, and The Light System, his exclusive distribution partner, have filed a $100 million federal lawsuit against EES in the Eastern District of New York alleging copyright infringement and misrepresentation. That case seeks to protect Religa’s intellectual property rights and to ensure that center owners are treated fairly.
The Light System supports center owners who have acted in good faith and who now find themselves facing legal action they should not have to bear. The Bowman case has drawn significant attention among center owners and industry observers, raising questions about EES’s treatment of its own customers. LA Weekly reported that other owners who made similar modifications were not sued, suggesting a selective legal strategy. Bowman has publicly stated that she was targeted because she discussed documented evidence of the true inventor’s identity, not because of any breach of contract.
TLS’s involvement in the broader legal dispute is centered on defending Religa’s rights as the inventor and protecting practitioners from the consequences of actions that arise from misrepresentation or inconsistent enforcement. The company emphasized its position that legal action should not be used to silence individuals who share factual information or who operate their centers in good faith.
The Light System stated that it will continue to cooperate with legal processes, present evidence where appropriate, and advocate for transparency and accountability in the industry. The company reaffirmed its support for center owners like Susan Bowman and for Robert J. Religa, the original inventor, whose rights are central to the pending federal litigation.
The Light System believes that all parties in this industry should be held to the same standard of truth and fairness. Their focus is to ensure that the facts are clear, that the rights of the inventor are protected, and that practitioners are not punished for seeking or sharing the truth.
Disclaimer: The information provided in this statement is for informational purposes only and reflects The Light System’s position regarding ongoing legal matters. It does not constitute legal advice or a legal determination of liability. All parties are presumed innocent unless and until proven otherwise in a court of law. The Light System makes no medical claims; its technology is not a medical device and is intended solely as a complementary wellness tool.
About The Light System
The Light System (TLS) is a U.S.-based wellness technology company specializing in energy-based systems that may support the body’s natural healing. Rooted in over 30 years of research, TLS combines photonic light collision, sacred geometry, light frequencies, and scalar fields to create immersive environments aimed at promoting clarity, calm, and energetic balance. While not a medical device, TLS is designed as a complementary tool for those exploring the energetic dimensions of well-being. For more information, visit thelightsystems.com and follow the company on Instagram at @thelight.system
###
For more information about The Light System, contact the company here:
The Light System The Light System media@thelightsystems.com
CEO Allan Evans Shares Q3 2025 Highlights and Provides Strategic Insight into the Company’s Plans
ORLANDO, FLORIDA / ACCESS Newswire / November 6, 2025 / Unusual Machines, Inc. (NYSE American:UMAC) (“Unusual Machines” or the “Company”), a leading provider of NDAA-compliant drone components, today announced it filed its Form 10-Q with the U.S. Securities and Exchange Commission for the third quarter of 2025 and provided the following letter to its shareholders from CEO Allan Evans.
Dear Shareholders,
This shareholder letter follows the completion of our third quarter of 2025. It has been another record revenue quarter. It is also our first profitable quarter with a net gain of $0.05 per share. We achieved the highest margins in our history and saw great returns on our corporate investments. We closed a financing for $48.5 million of gross proceeds during the quarter and raised another $72.1 million in gross proceeds last month on our ATM. We want to take this opportunity to provide context and deeper insights into our business and discuss Unusual Machines’ future.
Operations Update
Unusual Machines revenue for the third quarter was about $2.13 million which represents a year over year increase for the quarter of approximately 39%. This is our best revenue quarter of all time for the sixth consecutive quarter and was achieved through increasing enterprise sales offsetting weak consumer demand. For the first quarter ever, enterprise sales exceeded 50% of our total revenue. This allowed us to continue to improve gross margins to 39% which represents our highest quarterly margins to date. We expect the increase in enterprise sales to continue throughout 2025 and extend into 2026. We already have more than $16 million in purchase order commitments that we expect to fulfill in Q4 of 2025 through Q2 of 2026. We have a variety of GAAP results that obscure cashflow including $2.1 million in non-cash stock compensation expense and $5.8 million in unrealized gains from our investment strategy. Our non-GAAP adjusted numbers for the third quarter after taking into account the non-cash and non-recurring items resulted in an adjusted net loss from operations of $0.9 million (see Table 2).
Cash Position
We prioritize managing our cash position and cash flow. We started the third quarter with $38.9 million and finished the quarter with $64.3 million. We have subsequently raised an additional $72.1 million in gross proceeds through our ATM in October. The breakdown of the cash position change over the quarter (see Table 1) provides greater detail into our expenses. Total expenses are increasing as we rapidly grow, and we expect it to take a few quarters until revenue and operational gains catch up. We still absolutely prioritize prudent spending and are seeking to get to being consistently cash flow positive in late 2026.
Cap Table Changes
The financings have changed our capitalization table substantially. Unusual Machines now has 36.8 million of common shares outstanding with no shareholder to our knowledge owning more than 9.9% of the total. We have over $133 million in cash as of today (which includes the ATM, but excludes investments and inventory), and $0 in debt. Given the cash position, limited cash burn, improving revenues, and diversified shareholder base; we believe the company is in a very strong position to continue to grow quickly.
Looking Ahead
Our priorities moving forward are clear:
Grow Revenue: We are being aggressive. This quarter enterprise sales overtook consumer sales and we have over $16 million in purchase orders that we plan on fulfilling in less than a year. We expect these bookings to continue to increase as the government reopens and more of the 2025 and 2026 U.S. Government fiscal budgets are spent on drones.
Grow the Company: We have been scaling as quickly as we can. On Monday, we onboarded 31 new employees to help build motors and drone kits. We have expanded from our initial 7,000 square feet and expect to have approximately 70,000 square feet under lease by the end of 2025 with 60,000 square feet dedicated to manufacturing and fulfillment of drone components.
Get to Cash Flow Positive : We were profitable this quarter, but we don’t expect that to consistently happen over the next year. We are growing with the focus of our efforts driving us toward positive cash flow once we have scaled to the next revenue milestones. Accounting for growth, we expect to need $30 million in an annual revenue run rate to reach this target and are working toward getting there in 2026.
We are enthusiastic about the future of Unusual Machines. The company is in a great position to capitalize on enterprise sales and take advantage of macroeconomic factors to continue rapidly scaling. We are doing everything we can to capture market share and deliver great products for our customers. We appreciate you all for the confidence and support in our vision. Please reach out with any questions or comments.
Sincerely, Allan Evans CEO of Unusual Machines
Third Quarter Financial Results
Revenues totaled approximately $2.13 million for the three months ended September 30, 2025 as compared to $1.53 million for the three months ended September 30, 2024 which was a 39% increase for the third quarter year over year.
Revenues totaled approximately $6.30 million for the nine months ended September 30, 2025 as compared to pro forma revenue of $4.06 million for the nine months ended September 30, 2024, which represents a 55% increase for the first nine months year over year.
Gross margin for the third quarter was approximately 39%, which improved related to the increase in enterprise sales, increasing costs related to tariffs and expanding certain retail margins. Our gross margin for the first nine months of the year is approximately 34%.
Our loss from operations was approximately $4.9 million for the three months ended September 30, 2025 as compared to an operating loss of $1.4 million for the three months ended September 30, 2024. Included in this is non-cash stock compensation expense of $2.1 million and $0.4 million for the three months ended September 30, 2025 and 2024, respectively.
Interest income was $0.7 million for the three months ended September 30, 2025 related to interest earned from our cash balance which increased from our recent common stock offerings.
Unrealized gain from short term trading securities was $5.8 million for the three months ended September 30, 2025 related to investment gains from our investments made during the third quarter.
Net income attributable to common shareholders for the third quarter 2025 was approximately $1.6 million or $0.05 per share as compared to a net loss of approximately $2.1 million for the third quarter 2024 or $0.30 per share. The improvement in net income from a net loss position during the third quarter primarily related to the increase in our other income from unrealized gains in our short term trading securities and interest income.
We had approximately $64.3 million of cash as of September 30, 2025 as compared to $3.7 million as of December 31, 2024. The increase in cash primarily relates to our common stock offerings completed in May and July 2025 and cash exercise of warrants in February 2025. See table 1 for additional details.
For further information concerning our financial results, see the tables attached to this shareholders’ letter.
About Unusual Machines
Unusual Machines manufactures and sells drone components and drones across a diversified brand portfolio, which includes Fat Shark, the leader in FPV (first-person view) ultra-low latency video goggles for drone pilots. The Company also retails small, acrobatic FPV drones and equipment directly to consumers through the curated Rotor Riot e-commerce store. With a changing regulatory environment, Unusual Machines seeks to be a dominant component supplier to the fast-growing multi-billion-dollar US drone industry and the global defense business. According to Fact.MR, the global drone accessories market is currently valued at $17.5 billion and is set to top $115 billion by 2032.
This shareholder letter contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. These statements include: our expectation that we will improve gross margins, grow the Company and grow our revenues, expand enterprise sales throughout 2025 and extend into 2025, our ability to become cash flow positive and the timing, our ability to achieve rapid growth, our expectation concerning the impact from tariffs and achieve GAAP validation, that we will be successful leasing a new facility and expand our manufacturing footprint and build our headset production capabilities, our ability to anticipate market conditions, and the impact that the uncertain regulatory environment may have on our ability to accurately model for and grow our consumer business. The results expected by some or all of these forward-looking statements may not occur. Factors that affect our ability to achieve these results include our expectation that we will commence operations in our new Orlando manufacturing facility in September 2025, the continued availability of commercial real estate near our Orlando, Florida facilities, the availability of a satisfactory labor pool, potential supply chain issues, the impact from tariffs including inflation, and the Risk Factors contained in our Form 10-Q, filed with the SEC on May 8, 2025, Prospectus Supplement filed with the Securities and Exchange Commission (the “SEC”) on March 6, 2025 and in our Form 10-K for the year ended December 31, 2024. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Any forward-looking statement made by us herein speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
This shareholder letter includes both financial measures in accordance with Generally Accepted Accounting Principles, or GAAP, as well as non-GAAP financial measures. Generally, a non-GAAP financial measure is a numerical measure of a company’s performance, financial position or cash flows that either excludes or includes amounts that are not normally included or excluded in the most directly comparable measure calculated and presented in accordance with GAAP. Non-GAAP financial measures should be viewed as supplemental to, and should not be considered as alternatives to net income (loss), operating income (loss), and cash flow from operating activities, liquidity or any other financial measures. They may not be indicative of the historical operating results of the Company nor are they intended to be predictive of potential future results. Investors should not consider non-GAAP financial measures in isolation or as substitutes for performance measures calculated in accordance with GAAP.
Our management uses and relies on adjusted net loss, which is a non-GAAP financial measure. We believe that management, analysts, and shareholders benefit from referring to the following non-GAAP financial measure to evaluate and assess our core operating results from period-to-period after removing the impact of items that affect comparability. Our management recognizes that the non-GAAP financial measure has inherent limitations because of the excluded items described below.
We have included in Table 2 a reconciliation of our non-GAAP financial measure to the most comparable financial measure calculated in accordance with GAAP. We believe that providing the non-GAAP financial measure, together with reconciliation to GAAP, helps investors make comparisons between the Company and other companies. In making any comparisons to other companies, investors need to be aware that companies use different non-GAAP measures to evaluate their financial performance.
Table 1
Cash balance at June 30, 2025
$
38.9M
Q3 cash financings:
Registered direct offering
44.9M
Employee stock option exercises
0.2M
Interest income
0.7M
Q3 cash spend:
Normal operations
(1.0M)
Non-recurring legal and transaction expenses
(0.3M)
Non-recurring investor relations
(0.9M)
Inventory build up
(6.0M)
Motor facility equipment purchases
(1.3M)
Short-term investments
(11.0M)
Cash Balance at September 30, 2025
$
64.3M
Table 2
Net income for three months ended September 30, 2025
$
1.6M
Q3 non-cash income and expenses for the three months ended September 30, 2025:
Stock compensation expense
2.1M
Unrealized gains from short term investments
($5.8M)
Q3 non-recurring expenses for the three months ended September 30, 2025:
Investor relations
0.9M
Legal expenses related to acquisitions
0.3M
Adjusted net loss for the three months ended September 30, 2025
$
(0.9M)
Unusual Machines, Inc. Consolidated Condensed Balance Sheets
September 30, 2025
December 31, 2024
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents
$
64,285,750
$
3,757,323
Short-term investments
16,849,713
–
Accounts receivable
309,544
66,575
Inventories
3,118,491
1,335,503
Prepaid inventory
6,921,679
904,728
Other current assets
218,871
31,500
Total current assets
91,704,048
6,095,629
Non-current assets:
Property and equipment, net
1,728,661
570
Operating lease right-of-use asset, net
1,268,278
323,514
Other assets
84,693
59,426
Goodwill
7,402,906
7,402,906
Intangible assets, net
2,164,264
2,225,530
Unallocated purchase price provisional, Rotor Lab (See note 3)
8,725,968
–
Total non-current assets
21,374,770
10,011,946
Total assets
$
113,078,818
$
16,107,575
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable and accrued expenses
$
1,167,242
$
668,732
Operating lease liability
247,957
67,820
Deferred revenue
1,518,736
197,117
Contingent consideration
3,000,000
–
Total current liabilities
5,933,935
933,669
Non-current liabilities
Deferred tax liability
93,793
93,793
Operating lease liability – non-current
1,035,175
262,171
Total non-current liabilities
1,128,968
355,964
Total liabilities
7,062,903
1,289,633
Commitments and contingencies (See note 13)
Stockholders’ equity:
Preferred stock – $0.01 par value, 10,000,000 authorized (See note 10)
Series A preferred stock – $0.01 par value, 4,250 designated and 0 and 0 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively
–
–
Series B preferred stock – $0.01 par value, 1,000 designated and 0 and 0 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively
–
–
Series C preferred stock – $0.01 par value, 3,000 designated and 0 and 0 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively
–
–
Common stock – $0.01 par value, 500,000,000 authorized and 31,568,949 and 15,122,018 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively
Unusual Machines, Inc. Consolidated Condensed Statement of Operations For the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited)
Three months ended September 30,
Nine months ended September 30,
2025
2024
2025
2024
Revenues
$
2,134,588
$
1,531,264
$
6,300,857
$
3,561,303
Cost of goods sold
1,294,200
1,131,777
4,168,984
2,569,209
Gross Margin
840,388
399,487
2,131,873
992,094
Operating Expenses
Operations
636,705
218,126
1,343,584
544,220
Research and development
39,369
15,000
110,002
42,078
Sales and marketing
373,539
252,253
883,514
795,643
General and administrative
4,730,063
1,374,989
15,151,160
3,728,749
Depreciation and amortization
22,449
171
63,635
513
Total operating expenses
5,802,125
1,860,539
17,551,894
5,111,203
Loss from operations
(4,961,737
)
(1,461,052
)
(15,420,021
)
(4,119,109
)
Other income and (expense)
Interest income
715,489
180
942,755
180
Unrealized gain in short term investments
5,849,713
–
5,849,713
–
Interest expense
–
(41,465
)
–
(101,648
)
Loss on debt extinguishment
–
(685,151
)
–
(685,151
)
Change in fair value of derivatives and warrant liabilities
–
43,238
–
43,238
Other income and (expense)
6,565,202
(683,198
)
6,792,468
(743,381
)
Net income (loss)
$
1,603,465
$
(2,144,250
)
$
(8,627,553
)
$
(4,862,490
)
Net income (loss) per share attributable to common stockholders
Basic
$
0.05
$
(0.30
)
$
(0.38
)
$
(0.63
)
Diluted
$
0.05
$
(0.30
)
$
(0.38
)
$
(0.63
)
Weighted average common shares outstanding
Basic
30,002,179
7,147,866
22,610,516
7,749,285
Diluted
30,581,194
7,147,866
22,610,516
7,749,285
Unusual Machines, Inc. Consolidated Condensed Statement of Changes in Stockholders’ Equity For the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited)
Three and Nine Months Ended September 30, 2024
Series A, Preferred Stock
Series B, Preferred Stock
Series C, Preferred Stock
Common Stock
Additional Paid-In
Accumulated
Total Stockholders’
Shares
Value
Shares
Value
Shares
Value
Shares
Value
Capital
Deficit
Equity
Balance, December 31, 2023
–
$
–
190
$
2
–
$
–
3,217,255
$
32,173
$
5,315,790
$
(3,933,046
)
$
1,414,919
Issuance of common shares as settlement
–
–
–
–
–
–
16,086
161
64,183
–
64,344
Issuance of common shares, initial public offering, net of offering costs
–
–
–
–
–
–
1,250,000
12,500
3,837,055
–
3,849,555
Issuance of common shares, business combination
–
–
–
–
–
–
4,250,000
42,500
16,957,500
–
17,000,000
Conversion of preferred shares
–
–
(120
)
(1
)
–
–
600,000
6,000
(5,999
)
–
–
Net loss
–
–
–
–
–
–
–
–
–
(1,106,002
)
(1,106,002
)
Balance, March 31, 2024
–
$
–
70
$
1
–
$
–
9,333,341
$
93,334
$
26,168,529
$
(5,039,048
)
$
21,222,816
Conversion of preferred shares
–
–
(20
)
–
–
–
100,000
1,000
(1,000
)
–
–
Issuance of common shares, equity incentive plan
–
–
–
–
–
–
977,899
9,779
(9,779
)
–
–
Stock compensation expense – vested stock
–
–
–
–
–
–
–
–
346,854
–
346,854
Stock option compensation expense
–
–
–
–
–
–
–
–
14,389
–
14,389
Net loss
–
–
–
–
–
–
–
–
–
(1,612,238
)
(1,612,238
)
Balance, June 30, 2024
–
$
–
50
$
1
–
$
–
10,411,240
$
104,113
$
26,518,993
$
(6,651,286
)
$
19,971,821
Issuance of common shares, equity incentive plan
–
–
–
–
–
–
23,743
237
(237
)
–
–
Exchange of common shares for Series A preferred
4,250
43
–
–
–
–
(4,250,000
)
(42,500
)
42,457
–
–
Exchange of convertible note for Series C preferred
–
–
–
–
210
2
–
–
999,998
–
1,000,000
Stock compensation expense – vested stock
–
–
–
–
–
–
–
–
375,345
–
375,345
Stock option compensation expense
–
–
–
–
–
–
–
–
23,086
–
23,086
Net loss
–
–
–
–
–
–
–
–
–
(2,144,250
)
(2,144,250
)
Balance, September 30, 2024
4,250
$
43
50
$
1
210
$
2
6,184,983
$
61,850
$
27,959,642
$
(8,795,536
)
$
19,226,002
Unusual Machines, Inc. Consolidated Statement of Changes in Stockholders’ Equity For the Three and Nine Months September 30, 2025 and 2024 (Unaudited)
Three and Nine Months Ended September 30, 2025
Series A, Preferred Stock
Series B, Preferred Stock
Series C, Preferred Stock
Common Stock
Additional Paid-In
Accumulated
Other Comprehensive
Accumulated
Total Stockholders’
Shares
Value
Shares
Value
Shares
Value
Shares
Value
Capital
Deficit
Income
Equity
Balance, December 31, 2024
–
$
–
–
$
–
–
$
–
15,122,018
$
151,221
$
50,580,235
$
(35,913,514
)
$
–
$
14,817,942
Issuance of common shares, equity incentive plan
–
–
–
–
–
–
483,546
4,835
(4,835
)
–
–
–
Issuance of common shares for exercise of warrants
–
–
–
–
–
–
1,224,606
12,246
2,424,720
–
–
2,436,966
Stock compensation expense – vested stock
–
–
–
–
–
–
–
–
1,883,433
–
–
1,883,433
Stock compensation expense
–
–
–
–
–
–
–
–
22,940
–
–
22,940
Net loss
–
–
–
–
–
–
–
–
(3,266,279
)
–
(3,266,279
)
Balance, March 31, 2025
–
$
–
–
$
–
–
$
–
16,830,170
$
168,302
$
54,906,493
$
(39,179,793
)
$
–
$
15,895,002
Issuance of common shares, Management/BOD
–
–
–
–
–
–
208,336
2,082
(2,082
)
–
–
–
Issuance of common shares, Option exercises
–
–
–
–
–
–
94,650
947
366,923
–
–
367,870
Issuance of common shares, consulting services
–
–
–
–
–
–
4,630
46
(46
)
–
–
–
Issuance of common shares, advisory board
–
–
–
–
–
–
150,000
1,500
(1,500
)
–
–
–
Issuance of common shares, public offering
–
–
–
–
–
–
8,000,000
80,000
36,416,000
–
–
36,496,000
Stock option compensation expense
–
–
–
–
–
–
–
–
576,831
–
–
576,831
Stock Compensation expense – vested stock
–
–
–
–
–
–
–
–
4,936,497
–
–
4,936,497
Net loss
–
–
–
–
–
–
–
–
–
(6,964,739
)
–
(6,964,739
)
Balance, June 30, 2025
–
$
–
–
$
–
–
$
–
25,287,786
$
252,877
$
97,199,116
$
(46,144,532
)
$
–
51,307,461
Issuance of common shares, Management/BOD
–
–
–
–
–
–
589,232
5,892
(5,892
)
–
–
–
Issuance of common shares, Option exercises
–
–
–
–
–
–
25,250
253
133,487
–
–
133,740
Issuance of common shares, consulting services
–
–
–
–
–
–
1,539
15
(15
)
–
–
–
Issuance of common shares, public offering
–
–
–
–
–
–
5,000,000
50,000
44,851,000
–
–
44,901,000
Issuance of common shares, Rotor Lab acquisition
–
–
–
–
–
–
656,642
6,566
5,916,345
–
–
5,922,911
Issuance of common shares – warrant exercises
–
–
–
–
–
–
8,500
85
42,415
–
–
42,500
Stock compensation expense
–
–
–
–
–
–
–
–
114,960
–
–
114,960
Stock compensation expense – vested stock
–
–
–
–
–
–
–
–
1,987,600
–
–
1,987,600
Net income
–
–
–
–
–
–
–
–
–
1,603,465
–
1,603,465
Equity adjustment from foreign currency translation
–
–
–
–
–
–
–
–
–
–
2,278
2,278
Balance, September 30, 2025
–
$
–
–
$
–
–
$
–
31,568,949
$
315,688
$
150,239,016
$
(44,541,067
)
$
2,278
$
106,015,915
Unusual Machines, Inc. Consolidated Condensed Statement of Cash Flows For the Nine Months Ended September 30, 2025 and 2024 (Unaudited)
Nine Months Ended September 30,
2025
2024
Cash flows from operating activities:
Net loss
$
(8,627,553
)
$
(4,862,490
)
Depreciation and amortization
63,635
513
Stock compensation expense as settlement
–
64,344
Stock compensation expense
9,522,261
759,673
Unrealized gains from short term investments
(5,849,713
)
–
Bad debt
12,146
–
Change in fair value for warrant and derivative liabilities
–
(43,239
)
Loss on debt extinguishment, non-cash component
–
663,250
Change in assets:
Accounts receivable
(122,696
)
(73,109
)
Inventory
(1,746,100
)
337,562
Prepaid inventory
(6,016,951
)
(319,532
)
Other assets
(165,529
)
(29,100
)
Operating lease right-of-use asset
72,202
–
Change in liabilities:
Accounts payable and accrued expenses
406,399
630,595
Operating lease liabilities
(80,346
)
(33,056
)
Customer deposits and other current liabilities
1,137,953
186,076
Net cash used in operating activities
(11,394,294
)
(2,718,513
)
Cash flows from investing activities
Cash portion of consideration paid for acquisition of businesses, net of cash received
93,054
(852,801
)
Investments in short term securities
(11,000,000
)
–
Purchases of property and equipment
(1,550,687
)
–
Net cash used in investing activities
(12,457,633
)
(852,801
)
Cash flows from financing activities:
Proceeds from issuance of common shares, IPO
–
5,000,000
Proceeds from issuance of common shares, public offering
40,000,000
–
Proceeds from issuance of common shares, registered direct
48,500,000
–
Proceeds from option exercises
501,610
–
Proceeds from issuance of common shares, warrant exercises
2,479,466
–
Common share issuance offering costs
(7,103,000
)
(637,687
)
Net cash provided by financing activities
84,378,076
4,362,313
Net increase in cash
60,526,149
790,999
Effect of exchange rate changes on cash
2,278
–
Cash, beginning of period
3,757,323
894,773
Cash, end of period
$
64,285,750
$
1,685,772
Supplemental disclosures of cash flow information:
Non-cash consideration paid for assets acquired and liabilities assumed
$
8,922,911
$
19,000,000
Non-cash right of use asset and liability
$
973,443
$
–
Deferred acquisition costs
$
–
$
100,000
Deferred offering costs recorded as reduction of proceeds
SACRAMENTO, CA – October 22, 2025 – PRESSADVANTAGE –
Elite Auto Works, a Sacramento-based automotive protection specialist, reports continued growth in demand for Paint Protection Film applications as California drivers increasingly prioritize preventive vehicle care over reactive paint repairs. The company attributes this trend to heightened awareness about the long-term cost benefits of protecting factory paint from environmental damage.
The surge in PPF interest reflects a broader shift in how vehicle owners approach automotive maintenance. Rather than waiting for paint damage to occur from road debris, UV exposure, and environmental contaminants, drivers are choosing proactive protection that maintains their vehicle’s appearance and resale value. Elite Auto Works CA has positioned itself to meet this demand through precision installation techniques and partnerships with leading film manufacturers.
“We’re seeing a fundamental change in how California drivers think about vehicle maintenance,” said Ryan Schiller, founder and CEO of Elite Auto Works. “The harsh sun exposure and road conditions here make paint protection particularly valuable. Our clients understand that investing in quality PPF Service today prevents thousands of dollars in paint correction and refinishing costs down the road.”
Paint Protection Film technology has evolved significantly in recent years, with modern films offering self-healing properties that allow minor scratches to disappear with heat exposure. The films also provide UV protection that prevents paint oxidation and fading, a common concern in California’s intense sunlight. These advancements have made PPF an increasingly attractive option for both luxury and everyday vehicles.
Elite Auto Works offers comprehensive coverage options ranging from partial front protection to full-body applications. The company uses premium films including STEK DYNOshield and STEK DYNOmatt, both featuring advanced protective properties and multi-year warranties. The DYNOshield provides a glossy finish with a 10-year warranty, while the DYNOmatt offers a sophisticated matte appearance backed by a 7-year warranty.
Beyond paint protection, the company has expanded its protective services to include ceramic coatings, window tinting, and windshield protection films. This comprehensive approach allows vehicle owners to create multiple layers of defense against environmental damage. The ceramic coating services add hydrophobic properties that repel water and contaminants, while window tinting reduces interior heat and UV exposure.
The company’s growth mirrors industry data showing increased consumer investment in vehicle protection services nationwide. As new vehicle prices remain elevated and supply chain challenges persist, more owners are choosing to preserve their current vehicles rather than pursue frequent replacements.
Elite Auto Works CA maintains facilities in Sacramento and Granite Bay, serving Northern California with a range of automotive protection and enhancement services. The company has established partnerships with premium product manufacturers including Ceramic Pro, 3M Window Films, and serves as one of the few Northern California dealers for HRE wheels. Through these partnerships and a focus on installation excellence, the company continues to meet the evolving needs of California vehicle owners seeking to protect their automotive investments.
###
For more information about Elite Auto Works, contact the company here:
Elite Auto Works Ryan Schiller (916) 693-1071 info@eliteautoworksca.com 4555 Auburn Blvd #5, Sacramento, CA 95841
TORONTO, ON / ACCESS Newswire / November 3, 2025 / The Western Investment Company of Canada Limited (TSXV:WI) (“Western“) is pleased to announce the appointment of Keith Lau as Chief Actuary.
Mr. Lau is an accomplished actuarial leader with over ten years of experience in the Canadian property and casualty insurance sector. He brings significant expertise in pricing, reserving and reporting and provides a valuable strategic addition to Western’s growing decentralized insurance platform.
Before joining Western, Mr. Lau served in a range of actuarial roles, most recently as Cover Genius’ Head of Americas Pricing, where he helped to establish and scale the company’s actuarial function in North America. Before his tenure at Cover Genius, Mr. Lau held various roles of escalating responsibility in the actuarial practice at PwC, where he led actuary and audit engagements, played a central role in IFRS 17 implementation and served as a trusted advisor to executive teams on matters related to capital, reserves and solvency. Mr. Lau also spent time at RSA Insurance as a Senior Actuarial Analyst on the pricing team. Mr. Lau holds a Bachelor of Mathematics from the University of Waterloo and is a Fellow of the Casualty Actuarial Society and the Canadian Institute of Actuaries.
As Chief Actuary at Western, Mr. Lau will partner closely with Western’s finance and accounting functions to apply actuarial best practices and ensure compliance with regulatory requirements. Mr. Lau will oversee Western and its subsidiaries’ actuarial operations, including reserving, capital modelling, reviewing and maintaining liquidity, rating and reporting.
“I am delighted to welcome Keith to Western’s executive team. His proven experience across both high-growth businesses and regulated environments aligns strongly with Western’s long-term strategic objectives and will help us to drive Western’s continued success,” said Paul Rivett, Chief Executive Officer of Western.
As part of Mr. Lau’s compensation, Western has agreed to grant 806,452 restricted share units (RSUs) priced at $0.62 per share. Fifty percent of these RSUs will cliff vest after five years, with the balance cliff vesting after 10 years. The grant of these RSUs is subject to approval by the TSXV. It is Western’s expectation that the shares necessary to support these RSUs will be purchased in the open market and will not be issued from treasury.
About The Western Investment Company of Canada Limited
Western is an insurance and investment holding company focused on decentralized ownership of insurance businesses and centralized investment management. Western’s shares are traded on the Toronto Venture Exchange under the symbol WI.
For more information on Western, please visit its website at www.westerninvest.ca.
To add yourself to Western’s email news alert subscription please visit this link.
This news release may contain certain forward-looking information and statements, including without limitation statements pertaining to future results and plans for Western and its associated companies, acquisitions, financings and returns. Statements containing the words: ‘believes’, ‘intends’, ‘expects’, ‘plans’, ‘seeks’ and ‘anticipates’ and any other words of similar meaning are forward-looking. All statements included herein involve various risks and uncertainties because they relate to future events and circumstances beyond Western’s control.
The forward-looking statements are based on certain key expectations and assumptions made by Western, including expectations and assumptions concerning the ability of Western to successfully implement its strategic plans and initiatives.
Although Western believes that the expectations and assumptions on which the forward-looking statements made by Western are based are reasonable, undue reliance should not be placed on the forward-looking statements because no assurance can be provided that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, risks relating to regulatory compliance, risks relating to demand for the products and services provided by Fortress Insurance and other portfolio companies, risks relating to future growth prospects and business opportunities, risks that management is not able to execute its business strategy, and the impact of general economic conditions in Canada and the United States. A description of additional assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in Western’s disclosure documents on the SEDAR+ website at www.sedarplus.com.
The forward-looking statements contained in this news release are made as of the date hereof and Western undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
“Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.“
SOURCE: The Western Investment Company of Canada Limited
NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan
SHELTON, CONNECTICUT / ACCESS Newswire / November 5, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that the Company will be holding its Annual Shareholders Meeting at 10 am on Saturday, November 8th, 2025, at the Hampton Inn & Suites Stamford, CT.
Event Information:
Event
NanoViricides Annual Shareholders Meeting
Date
Saturday, November 8, 2025
Time
10:00 am
Location
Hampton Inn & Suites Stamford, 26 Mill River Street, Stamford CT 06902.
Requirements
Only current shareholders are eligible to attend. No recording using any devices will be permitted. Any reporters, journalists, or writers must identify themselves with their affiliation at the registration desk. Company retains the right to inspect the attendee’s valid US identification.
Anil R. Diwan, PhD, President and Executive Chairman of the Company will review the Company’s progress towards clinical trials, and the near future planned clinical trials.
Currently, the Company is fully engaged in completing the Clinical Trial Application (CTA) and initiating a Phase II clinical trial for the evaluation of NV-387 as a treatment for MPox. This clinical trial will be conducted in the Democratic Republic of Congo (DRC). The more severe strains of MPox Clade Ia and Clade Ib are prevalent in DRC. In contrast, the less severe Clade IIa and IIb strains have become endemic in certain Western countries including the USA, but only in specific populations such as men having sex with men (MSM), and HIV-infected immunocompromised patients. MPox Clade II is prevalent in Western African countries.
Recently, three new MPox Clade I cases have occurred in California. All three cases required hospitalization, but are recovering. These cases were not related to travel to the African countries, and authorities suspect that community spread with asymptomatic transmission may be occurring (https://thehill.com/policy/healthcare/5572528-california-mpox-concerns/). This raises the possibility of MPox Clade I spreading further either as small outbreaks, as we have witnessed for Measles recently, or as local epidemics. The potential for a widespread pandemic is low because transmission of the virus requires close dermal contact with infected skin lesions. However, preparedness is warranted.
The case fatality rate (CFR) of MPox Clade I has ranged from about 9% down to 1.5%. This decline has been attributed to improved standard of care. In contrast, the CFR for MPox Clade II is low, at about 0.2%.
There is no approved treatment for MPox. For prevention, a smallpox vaccine called Jynneos® is said to have a vaccine effectiveness rate of 66% with two doses and 36% with a single dose in MPox Clade II (N Engl J Med 2023;388:2434-43, DOI: 10.1056/NEJMoa2215201).
“We believe NV-387 could be the answer to the challenges posed by rising MPox Clade I cases, and also the on-going MPox Clade II cases, in the USA,” declared Anil R. Diwan, PhD, President of the Company, asserting, “The current countermeasures in the US Government Strategic National Stockpile are clearly deficient and inadequate for an effective public health response to a MPox epidemic should the virus spread further.”
A drug approved for smallpox under the FDA “Animal Rule”, namely TPOXX ® (tecovirimat) was mobilized during the 2022 MPox Clade II epidemic. Clinical trials of this drug failed to prove effectiveness in treating MPox Clade I or Clade II infections. The utility of tecovirimat as a treatment is questionable because a single point mutation in a viral protein enables the virus to escape the drug.
Another drug, TEMBEXA® (brincidofovir) was also approved for smallpox under the FDA “Animal Rule”. Its clinical trial (called “MOSA”) for treating MPox in Africa started with fanfare in January, 2025, and top-line results were promised by end of first quarter of 2025. The current status of this clinical trial is unknown. The utility of TEMBEXA for treating MPox in an epidemic scenario is highly questionable because the drug carries a “black box warning”, requires medical monitoring after dosing, produces gastrointestinal adverse events, produces hepatic adverse events, has caused discontinuations in 5% of patients in clinical trials, is a known mutagen, carcinogen, teratogen, has embryo-fetal toxicity risk, and may cause male infertility, according to the drug prescribing information (https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214460s000,214461s000lbl.pdf).
TPOXX and TEMBEXA, as potential treatments, and Jynneos as a preventative vaccine, have been stockpiled by the US Government as preparedness measures for potential smallpox bioterrorism event, and have been mobilized in response to MPox cases.
In contrast to these drugs, NV-387 has demonstrated a strong safety and tolerability profile in Phase I healthy subjects clinical trial, and in non-clinical animal model studies. NV-387 has also demonstrated strong effectiveness in animal models of orthopoxvirus infections when directly compared with tecovirimat. The virus is highly unlikely to escape the attack by NV-387 because the drug NV-387 is created by mimicking the host-side “landing sites” of the virus in the human body, which do not change even as the virus mutates.
NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.
Plymouth, Minnesota – October 22, 2025 – PRESSADVANTAGE –
The Minnesota Center for Emotionally Focused Therapy (MNCEFT) hosted its largest-ever EFT Externship from September 17-20, 2025, at the Humphrey Conference Center on the University of Minnesota’s Minneapolis campus, with 54 licensed professionals and interns participating in the intensive four-day training program.
The record-setting attendance marks a significant milestone for Emotionally Focused Therapy education in Minnesota, as mental health professionals seek advanced training in evidence-based couples therapy approaches. The externship, which serves as the foundational step toward EFT certification, provided participants with 24 Continuing Education Units, including two cultural CEUs.
Renee Segal, MA, LMFT, a Certified EFT Supervisor and owner of Evolve Therapy in Minnetonka, Minnesota, served as one of the supervising professionals for the training. With over two decades of experience in couples counseling, Segal has established herself as a central figure in the Minnesota EFT community, supporting therapists in applying Emotionally Focused Therapy through mentorship and supervision.
“The overwhelming response to this externship demonstrates the growing recognition among mental health professionals that couples need specialized, attachment-based interventions,” said Segal. “EFT provides therapists with a clear roadmap for helping couples break destructive patterns and build lasting emotional connections. The diversity of participants, from licensed therapists to pre-licensed professionals, shows how the field is evolving to meet the complex needs of modern relationships.”
Emotionally Focused Therapy, developed by Dr. Sue Johnson and Dr. Les Greenberg, represents a structured, attachment-based approach to couples therapy that helps partners identify and transform negative interaction cycles while building secure emotional bonds. The September externship included theoretical instruction, live demonstrations, and experiential role-play sessions designed to help clinicians apply EFT techniques with confidence in their practices.
The training attracted a diverse group of mental health professionals, including licensed therapists, psychologists, counselors, and pre-licensed practitioners. MNCEFT offered tuition ranging from $575 to $1,075, with scholarship options available for BIPOC, LGBTQIA2+, and underrepresented clinicians committed to serving marginalized communities.
The success of the September externship reflects broader trends in mental health care, where practitioners increasingly seek specialized training in evidence-based couples therapy modalities. The event was hosted independently by MNCEFT and not sponsored by the University of Minnesota, though it utilized the university’s conference facilities.
MNCEFT has announced that the next externship is scheduled for early Fall 2026, with official dates to be announced on their website.
Evolve Therapy, under Segal’s leadership, employs 12 therapists trained in EFT and specializes in working with couples facing various challenges, including affairs, addictions, betrayal, communication issues, unmet emotional needs, attachment injuries, narcissism, and unhealthy relationship patterns. The practice offers comprehensive services, including relationship counseling, individual therapy, premarital counseling, and specialized treatment for affairs and sex addiction. Additionally, the clinic provides supervision and training for therapists, therapy for mental health professionals, and practicum placement opportunities for students pursuing careers in mental health.
###
For more information about Evolve Therapy, contact the company here:
MARIETTA, GA – November 05, 2025 – PRESSADVANTAGE –
MoldStar Remediation is urging residents in Marietta to pay close attention to the dangers of Stachybotrys chartarum, commonly known as black mold. The company reports that this toxic fungus continues to cause health concerns in homes and buildings across Cobb County due to persistent moisture and poor indoor ventilation.
Stachybotrys chartarum thrives in damp, water-damaged environments, feeding on cellulose-based materials such as drywall, wood, and insulation. MoldStar Remediation has observed that local conditions in Marietta, including seasonal humidity and heavy rainfall, create ideal environments for black mold growth. When left untreated, it can produce harmful mycotoxins that lead to respiratory distress, allergic reactions, and other long-term health problems.
“Mold doesn’t just appear in neglected spaces,” said Alex Laldin, Marketing Director at MoldStar Remediation. “Even small leaks or humidity issues can create the conditions for Stachybotrys to grow. People often underestimate the impact it can have on their health and home.”
Black mold colonies often appear as dark, slimy patches on surfaces and emit a distinct musty odor. While visible mold can be alarming, the greater concern lies in the microscopic spores that spread through the air. Once airborne, these spores can settle on new surfaces, leading to widespread contamination that often goes unnoticed. According to MoldStar Remediation, homeowners frequently discover hidden mold behind walls, under flooring, or around HVAC systems after health symptoms appear.
Exposure to Stachybotrys can affect people differently based on their sensitivity, health status, and length of exposure. Common symptoms include coughing, nasal congestion, itchy eyes, and skin irritation. Individuals with asthma or weakened immune systems may experience more serious effects, such as difficulty breathing, chronic inflammation, or prolonged fatigue. In extreme cases, prolonged exposure to toxic black mold can cause neurological symptoms, migraines, and even immune suppression.
“People don’t always connect their health symptoms to their environment,” Laldin explained. “If someone has been feeling constantly sick or tired, or if they have allergies that don’t seem to improve, mold might be playing a role. It’s something we see frequently in our inspections.”
MoldStar Remediation stresses that identifying dangerous levels of Stachybotrys requires more than surface cleaning. Professional mold testing is often necessary to detect airborne spores and assess contamination levels. Specialists use tools such as air sampling and moisture mapping to locate hidden mold sources. Once detected, remediation efforts must include removing contaminated materials and addressing the underlying moisture issues that allowed the mold to form.
“The key is not just cleaning what you can see,” Laldin said. “You have to eliminate the moisture problem and make sure spores are removed from the air. Otherwise, the mold will return.”
According to environmental health agencies, the primary way to prevent mold growth is to control indoor humidity. Keeping indoor moisture levels below 60 percent significantly reduces the risk of mold formation. MoldStar Remediation recommends using dehumidifiers, ensuring proper ventilation in bathrooms and kitchens, and repairing leaks quickly. Regular inspections of attics, basements, and crawlspaces are also effective in preventing long-term problems.
Black mold growth is especially common in water-damaged buildings. After floods, roof leaks, or plumbing failures, moisture can remain trapped in materials for weeks. Without professional drying and inspection, this trapped moisture can create ideal conditions for mold colonization. “After any kind of water damage, even if it looks dry on the surface, there’s often moisture deep inside walls and floors,” Laldin said. “That’s why post-flood inspections are so important in Marietta homes.”
Stachybotrys spores are particularly concerning because of their ability to produce mycotoxins. These toxic compounds can cause cellular inflammation and inhibit protein synthesis in human cells. For people with compromised immune systems, such exposure can lead to severe respiratory illnesses or chronic inflammatory conditions. Infants, elderly individuals, and those with existing health issues are especially vulnerable to long-term effects.
Professional remediation is the safest way to address extensive mold infestations. Certified technicians use HEPA-filtered equipment to remove spores from the air and specialized cleaning agents to neutralize contamination. MoldStar Remediation emphasizes that do-it-yourself cleaning may not be enough for toxic mold because improper handling can release spores and worsen contamination.
“Bleach and surface cleaners don’t solve the problem,” Laldin noted. “They can make the surface look clean, but the spores remain active underneath. That’s why professional removal and moisture control are critical.”
Air purification also plays an important role in maintaining a healthy indoor environment. HEPA air purifiers can capture mold spores and other allergens, reducing their presence in the air. Regular filter changes and ongoing maintenance of HVAC systems are essential for keeping air quality high and preventing mold recurrence.
MoldStar Remediation continues to educate homeowners throughout Marietta on the importance of moisture prevention and early detection. Simple actions such as inspecting for leaks, using exhaust fans, and maintaining proper drainage around the home can significantly reduce mold risks.
“Prevention is always better than remediation,” Laldin said. “By keeping your home dry and ventilated, you can avoid the serious health and financial costs that come with black mold.”
Residents who suspect black mold in their homes should schedule a professional inspection as soon as possible. Testing can determine whether Stachybotrys is present and identify the areas most affected. Prompt remediation helps restore indoor safety and protects families from potential long-term health effects.
MoldStar Remediation encourages Marietta homeowners to stay proactive in maintaining a healthy indoor environment. Regular cleaning, humidity control, and immediate response to water damage can make a lasting difference in preventing Stachybotrys growth.
For more information about black mold inspection, testing, and remediation in Marietta, contact MoldStar Remediation.
###
For more information about MoldStar Remediation, contact the company here:
MoldStar Remediation Alex Laldin (404) 585-7319 moldstarremediationpr@gmail.com 3926 Samuel Chapel Ct, Marietta, GA 30066
Braga Outdoor Lighting, a family-owned custom illumination specialist, announces the expansion of its comprehensive lighting services throughout the Denver metropolitan area, strengthening its commitment to transforming residential and commercial properties with innovative outdoor and indoor lighting solutions.
The expansion reflects growing demand for professional lighting services that combine aesthetic enhancement with energy-efficient technology. The company’s comprehensive approach addresses landscape lighting, holiday displays, commercial illumination, and recently expanded indoor lighting services, positioning the firm as a single-source provider for property owners seeking cohesive lighting design.
“The Denver market has shown tremendous interest in lighting solutions that balance visual impact with sustainability,” said Sophia Williams, spokesperson from Braga Outdoor Lighting. “Our expansion allows us to serve more properties across the metropolitan area while maintaining the personalized service and attention to detail that defines our approach to every project.”
The company’s landscape lighting services focus on illuminating gardens, pathways, and architectural features to extend outdoor enjoyment into evening hours. Each installation utilizes weather-resistant fixtures specifically selected to withstand Colorado’s variable climate conditions. The design process emphasizes highlighting unique property features while improving safety and security through the strategic placement of lighting elements.
Commercial properties benefit from tailored solutions that enhance curb appeal and functionality. The company’s commercial division specializes in LED installations that reduce energy consumption while providing superior illumination for businesses. Security lighting integration adds another layer of value for commercial clients concerned with property protection and visitor safety.
Seasonal holiday lighting represents a significant component of the company’s service portfolio. The full-service approach includes design consultation, professional installation, and post-season removal, allowing property owners to create festive displays without the challenges of personal installation and storage.
Those interested in learning more about Braga Outdoor Lighting’s expanded services can visit the website for detailed information and project galleries. The company offers consultations to assess lighting needs and develop customized solutions for each property.
The recent addition of indoor lighting services complements the established outdoor offerings. Interior solutions include recessed lighting, chandelier installation, LED retrofitting, accent lighting, and smart home integration. Certified electricians conduct comprehensive assessments to identify opportunities for improved illumination and energy efficiency upgrades.
Technology integration remains central to the company’s service delivery. Smart home compatibility allows clients to control lighting systems through smartphones, voice commands, or automated scheduling. This technological capability extends to both indoor and outdoor installations, providing unified control across entire properties.
Energy efficiency drives much of the company’s design philosophy. LED technology offers significant reductions in energy consumption compared to traditional lighting methods. The design team works closely with clients to identify opportunities for energy savings while enhancing visual appeal and functionality.
As an approved vendor for industry leaders Lutron, Oelo, and Watts, the company ensures access to high-performance lighting components backed by comprehensive warranties. These partnerships enable the delivery of durable solutions that maintain performance standards over extended periods.
Braga Outdoor Lighting continues to serve the Denver metropolitan area with a decade of experience in custom lighting solutions. The family-owned business maintains its focus on quality craftsmanship, innovative design, and reliable service that has established its reputation in the Colorado lighting industry. Learn more about Braga Outdoor Lighting on their website.
###
For more information about Braga Outdoor Lighting, contact the company here:
Braga Outdoor Lighting Sophia Williams 3106945655 sophia@truenorthsocial.com 18172 e Arizona Ave Unit B, Aurora, CO 80017
